These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Oral and topical antihistamines: pharmacologic properties and therapeutic potential in ocular allergic disease. Jaanus SD J Am Optom Assoc; 1998 Feb; 69(2):77-87. PubMed ID: 9549258 [TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Abelson MB; Greiner JV Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212 [TBL] [Abstract][Full Text] [Related]
4. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. Ahluwalia P; Anderson DF; Wilson SJ; McGill JI; Church MK J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467 [TBL] [Abstract][Full Text] [Related]
5. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids. Blaiss MS Curr Med Res Opin; 2008 Mar; 24(3):821-36. PubMed ID: 18257976 [TBL] [Abstract][Full Text] [Related]
6. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Galatowicz G; Ajayi Y; Stern ME; Calder VL Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Bielory L; Lien KW; Bigelsen S Drugs; 2005; 65(2):215-28. PubMed ID: 15631542 [TBL] [Abstract][Full Text] [Related]
10. Multiple action agents and the eye: do they really stabilize mast cells? Lambiase A; Micera A; Bonini S Curr Opin Allergy Clin Immunol; 2009 Oct; 9(5):454-65. PubMed ID: 19652595 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332 [TBL] [Abstract][Full Text] [Related]
13. Evidence-based study design in ocular allergy trials. Katelaris CH; Bielory L Curr Opin Allergy Clin Immunol; 2008 Oct; 8(5):484-8. PubMed ID: 18769206 [TBL] [Abstract][Full Text] [Related]
14. The role of histamine in ocular allergy. Ohbayashi M; Manzouri B; Morohoshi K; Fukuda K; Ono SJ Adv Exp Med Biol; 2010; 709():43-52. PubMed ID: 21618886 [TBL] [Abstract][Full Text] [Related]
15. Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis. Fukuda K; Ohbayashi M; Morohoshi K; Zhang L; Liu FT; Ono SJ J Allergy Clin Immunol; 2009 Oct; 124(4):827-33.e2. PubMed ID: 19660804 [TBL] [Abstract][Full Text] [Related]